Short Interest in Synthetic Biologics, Inc. (SYN) Decreases By 12.6%

Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) saw a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 6,268,579 shares, a decline of 12.6% from the October 31st total of 7,176,264 shares. Based on an average daily volume of 909,188 shares, the short-interest ratio is presently 6.9 days. Approximately 5.5% of the shares of the company are short sold.

Shares of Synthetic Biologics (NYSEAMERICAN SYN) opened at $0.57 on Monday. Synthetic Biologics has a 12 month low of $0.41 and a 12 month high of $1.05.

Synthetic Biologics (NYSEAMERICAN:SYN) last announced its quarterly earnings data on Wednesday, November 1st. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.10).

Several research firms have weighed in on SYN. ValuEngine raised shares of Synthetic Biologics from a “strong sell” rating to a “sell” rating in a research report on Friday, August 18th. Zacks Investment Research cut shares of Synthetic Biologics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. Finally, BidaskClub cut shares of Synthetic Biologics from a “hold” rating to a “sell” rating in a research note on Saturday, November 4th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $3.92.

TRADEMARK VIOLATION NOTICE: This story was first posted by Week Herald and is the property of of Week Herald. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at

About Synthetic Biologics

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Receive News & Ratings for Synthetic Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc. and related companies with's FREE daily email newsletter.

Leave a Reply